Bayer pharmaceuticals and EndoCeutics are performing trials for a treatment that may be the answer to the problem of certain aspects of female sexual dysfunction. It goes by the name of Vaginorm and eases the effects of vaginal dryness.
Phase 3 trials are being carried out presently in Canada and the US and so far, the outlook is a positive one. Vaginorm is inserted into the vagina and not only lubricates the area but the compound serves to increase DHEA levels which affect the functioning of the female genital organ. A decrease in DHEA causes the symptoms of menopause. They estimate that Vaginorm could help 75% of women who are experiencing sexual difficulties post menopause.
This is an exciting time for both Bayer and EndoCeutics and hopefully the results will justify the $330 million spent on research costs.